Dialysis industry news

Stories from the dialysis comunity across the globe.



Shares of NxStage Medical, Inc. (NASDAQ:NXTM) Drops by -0.55% - OTC Outlook PDF Print

NxStage Medical, Inc. (NASDAQ:NXTM) has dropped 0.55% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 30.34% in the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 5.54% and the outperformance increases to 37.54% for the last 4 weeks.

For the current week, the company shares have a recommendation consensus of Buy. NxStage Medical, Inc. (NASDAQ:NXTM) rose 2.31% or 0.41 points on Friday and made its way into the gainers of the day. After trading began at $17.47 the stock was seen hitting $18.5 as a peak level and $17.358 as the lowest level. The stock ended up at $18.17. The daily volume was measured at 572,622 shares. The 52-week high of the share price is $19.63 and the 52-week low is $11.5. The company has a market cap of $1,153 million. Nxstage Medical, Inc. is up 9% in the last 3-month period. Year-to-Date the stock performance stands at 1.34%. The company shares have rallied 38.28% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $15.54 and the 200 day moving average is recorded at $16.68. S&P 500 has rallied 1.35% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards $21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $15 per share. The higher price estimate target is at $24 according to the Analysts. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...

 
Shares of Fresenius Medical Care Corporation (NYSE:FMS) Drops by -7.61% - American Trade Journal PDF Print

Fresenius Medical Care Corporation (NYSE:FMS) has lost 7.61% during the past week and dropped 12.15% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 1.95%. Fresenius Medical Care Corporation (NYSE:FMS) has underperformed the index by 7.31% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

For the current week, the company shares have a recommendation consensus of Buy. Fresenius Medical Care Corporation (NYSE:FMS) witnessed a decline in the market cap on Friday as its shares dropped 3.75% or 1.48 points. After the session commenced at $39.13, the stock reached the higher end at $39.32 while it hit a low of $38.02. With the volume soaring to 177,397 shares, the last trade was called at $38.02. The company has a 52-week high of $44.34. The company has a market cap of $23,739 million and there are 624,394,000 shares in outstanding. The 52-week low of the share price is $32.4. Fresenius Medical Care AG & Co. KGAA has dropped 12.03% during the last 3-month period . Year-to-Date the stock performance stands at 3.42%. The company shares have rallied 9.22% in the past 52 Weeks. On June 4, 2015 The shares registered one year high of $44.34 and one year low was seen on October 16, 2014 at $32.4. The 50-day moving average is $41.93 and the 200 day moving average is recorded at $41.58. S&P 500 has rallied 1.35% during the last 52-weeks. Fresenius Medical Care Corporation (NYSE:FMS): 5 analysts have set the short term price target of Fresenius Medical Care Corporation (NYSE:FMS) at $43.61. The standard deviation of short term price target has been estimated at $5.04, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 50 and $39 respectively. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.

...

 
Doc's neglect kills patient, kin get Rs15L payout - Times of India PDF Print
<![CDATA[ .userptwrpr{position:relative} .bgtooltip{background: url(/photo/12936810.cms) no-repeat; width: 270px; height: 116px !important; z-index: 999 !important; left: -82px; top: 7px;Position:absolute; display:none} .bghdn{color: #fff; font-weight: bold; text-transform:uppercase; text-align:center; margin:0px; padding:26px 0 0; font-size:13px; font-family:arial, sans-serif; line-height:18px} .bgcontent{color: #999; font: 12px/16px Arial,Helvetica,sans-serif; padding: 3px 10px 0; display:block;} .bgcontent a{color:#999!important; text-decoration:none!important; float:none} .bgcontent a:hover{color:#999; text-decoration:underline;} /*#header .user_area .point:hover .bgtooltip{display:block!important}*/ .userptwrpr:hover .bgtooltip{display:block!important} .blk_arrow_img, .rotimg1{ background:url("/photo/45131686.cms") no-repeat scroll 0 0 !important; width: 9px;height: 8px;cursor: pointer;margin-left: 5px;position:relative; display:inline-block; vertical-align:middle; } .tpgrynw1 #srchsel3 .rotimg2{ background:url("/photo/45131686.cms") no-repeat scroll 0 -16px !important; transform: rotate(0deg); } ]]> : Sign In/ Create AccountThe Times of India
Indiatimes
Web (by Google)
Video
Photos
<![CDATA[body{display: block !important;}]]><![CDATA[@media (max-width: 1100px){.rightfixedAd{display:none;}]]><![CDATA[ .liveS_container{border:solid 1px silver; background:#eee; font-family:arial; margin-bottom:10px;display:none;} .liveS_container .sbtn{display:block; background-color:#df4547; color:White; font-weight:bold; padding:5px 5px 4px; float:left; margin-right:15px; font-size:12px; position:static; width:auto; height:auto; line-height:14px} .liveS_container h3{color:black; padding:0 4px 0 0; margin:0 10px 0 0; float:left; font-size:19px;} .liveS_container .live_link{dispaly:block; color:#df4547; float:left; font-size:11px; border-left:ridge 2px silver; font-weight:bold; margin:6px; padding-left:14px; cursor:pointer; text-decoration:none;} .streaming_box{width:300px; height:245px; border:solid 0px black; position:fixed; bottom:0; right:0; display:none;z-index:1011; background-color:White; padding:10px; cursor:move;} .liveS_container .close_s{display: block; border-radius: 100%;padding:2px 1px 14px 2px;border: solid 1px silver;color: silver;text-decoration: none;cursor: pointer;float: right;width: 13px;height:0px;text-align: center;margin:7px 5px 0 0; font-size:12px;} .liveS_container .close_s:hover{background-color:Gray; color:White;} .vtitle{background-color:black; color:White; font-size:11px; padding:3px; margin:0; border-bottom:solid 1px white; font-family:arial;} .close_v{display:block; padding:5px 8px; background:red; font-family:arial; color:white; font-size:12px; cursor:pointer; float:right; position:absolute; top:100%; right:0;} #player{} #watchlive{padding:5px; cursor:pointer} .box_head{padding:5px; font-size:11px; cursor:move; background:black; font-weight:light; color:White; position:relative; border-bottom:solid 1px white;} .box_head .livetv_title{display: block; width: 240px; float: left; line-height:12px;} .box_head .watchlive_tv{color: rgb(20, 151, 168); font-size: 11px; font-weight: bold; font-family: arial; display: block; float: right; border-left: solid 1px rgb(20, 151, 168); width: 42px;padding-left: 5px; cursor:pointer;} .box_head .watchlive_tv:hover{color:White; text-decoration:underline;} ]]>Jehangir B GaiJehangir B Gai | Aug 23, 2015, 01.00 AM ISTLogin Login MUMBAI: Can a doctor jeopardize a patient's life by discontinuing treatment? Case Study: Yogesh Kumar, a CRPF constable attached to the Customs department of the government of India at Jaipur, developed kidney problems and was in critical condition due to renal failure. He was admitted to Bombay Hospital under Dr Ashok Kripalani, consultant nephrologist and incharge of the hospital's artificial kidney unit. He was advised renal transplant, for which the required advance of Rs 1,48,000 was deposited by the authorities under the Central Government Health Scheme (CGHS). The kidney donor was also kept ready. Meanwhile, Yogesh was repeatedly admitted and discharged from the hospital, being advised haemodialysis each time. The last discharge was given on December 31, 1997, after a nurse's complaint that Yogesh had slapped her. The discharge card had no advice and merely prescribed certain medications. Yogesh's parents repeatedly requested that the doctor continue treatment as his condition was critical and discharging him would be against medical ethics. When their pleas fell on deaf ears, they took him to Delhi. He could not get admitted to AIIMS, but was admitted to Sir Ganga Ram Hospital, where he was put on dialysis. After discharge, he returned to Jaipur, where he was admitted to Santokba Durlabhji Hospital, where he died on February 8, 1998. The medical certificate of death stated that he died of "cardiac arrest due to ESRD—septicaemia— Hepatitis B positive case of chronic renal failure". Yogesh's parents filed a consumer complaint alleging that their son had died due to the negligence of Bombay Hospital and its doctors who forcibly discharged him. Dr Kripalani contested the case, contending that the complaint was time-barred, that it was not maintainable as no fe8es had been paid to him and objected to Yogesh's wife not being joined in the proceedings. On merits, Dr Kripalani said that Yogesh was suffering from end-stage renal disease, for which he was put on dialysis and was advised kidney transplant. Meanwhile, Yogesh was admitted on four occasions when he was treated as per standard protocol. The government of Maharashtra had granted permission for kidney transplant on August 8,1997, which was valid for 90 days, until November 7,1997, but Yogesh did not approach him along with a kidney donor during this period. The fee which had been deposited was partly refunded, since the transplant could not be carried out in the sanctioned period. Yogesh was of sound mind, yet he slapped the nurse merely because she had woken him up to check his vital parameters such temperature, blood pressure on her routine round. Such behaviour was unacceptable, and hence Yogesh was discharged. What happened thereafter was not the concern of the hospital or its doctors, and they could not be held liable for his death. Yogesh's parents pointed out that it was the hospital which had applied for sanction of kidney transplant. The permission granted by the Maharashtra government was not communicated to them either by the hospital or its doctors. They learnt of the permission after it had lapsed, when they brought Yogesh in for a routine admission. So, even though there was a ready donor, the transplant could not be carried out because of non-communication of the permission. Commission's findings: The hospital was billing Yogesh and Dr Kripalani was remunerated by the hospital on the basis of a tie-up, his services were not free. The commission concluded that Yogesh was a consumer, and held the complaint to be maintainable. Both, the doctor and the hospital could not produce evidence to show that the patient had been told of the nod for the kidney transplant. As Yogesh did not know of this, the sanction lapsed after 90 days and no transplant could be done, leading to his death. The failure to inform the patient about the sanction was held to be a deficiency in service. There was no police complaint, internal inquiry report, or other evidence to substantiate that Yogesh had slapped or misbehaved with the nurse. Yet, he was mercilessly discharged without any follow-up advice, even though a follow-up was required after he had undergone an AV fistula procedure just a day prior to the forceful discharge. This too was held as a deficiency in service. Yogesh's parents had initially filed the complaint before the Rajasthan state commission in time, but it remained pending for a year before being returned for lack of territorial jurisdiction. The complaint was then filed before the Maharashtra state commission, with a delay of about six weeks. The state commission considered this to be nominal and unintentional, deeming it fit to condone the delay. It concluded that there was medical as well as professional negligence, as Dr. Kripalani had committed breach of his duty to treat Yogesh, by abruptly withdrawing his services without sufficient notice and by forcibly 8discharging him. By its judgment of July 31, delivered by Narendra Kawde for the Bench along with Shashikant Kulkarni, the Maharashtra state commission jointly held Dr Kripalani and Bombay Hospital liable to pay a compensation of Rs 14.5 lakh, along with interest at 10% p.a. from February 5, 2000 until the date of payment. In addition, Rs 1 lakh compensation for mental trauma and Rs 25,000 towards costs was awarded. Yogesh's father was directed to furnish an indemnity bond that Yogesh's wife and daughter would be given their respective shares of the compensation since they were not a party to the litigation. Conclusion: A doctor is duty-bound to preserve life, and cannot jeopardise a patient's life by withdrawal of services. (The author is a consumer activist and has won the govt. of India's National Youth Award for Consumer Protection. His email is This e-mail address is being protected from spambots. You need JavaScript enabled to view it )

http://timesofindia.indiatimes.com/followceleb.cms?alias=renal,patient,Hospital,Doctor,discharged

Stay updated on the go with Times of India News App. Click here to download it for your device.

More from The Times of India

...

 
Renal considerations: When stones strike - The Express Tribune PDF Print
Renal considerations: When stones strike - The Express Tribune

Are you at risk for kidney stones? Find out how to steer clear of this common ailment. DESIGN BY HIRA FAREED

Are you at risk for kidney stones? Find out how to steer clear of this common ailment.

Symptoms

Appearance of blood in urine

Pain in the abdomen, flank, or groin. The pain is usually sudden, very severe and intermittent. The pain radiates from the back, down the flank, and into the groin.

Treatment

A majority of stones pass spontaneously from the body within 48 hours. Factors that influence this passage include:

Weight

Prior stone passage

Prostate enlargement

Pregnancy

The size of the stone

If a stone does not pass, a urology specialist may be needed. Routine treatment includes pain relief measures, hydration, and a course of antibiotics in case of an infection.

Eight to 10 glasses of water a day

“The correct way to see if you’re meeting your body’s fluid requirement is by the urine output. You may be drinking eight to 10 glasses of water, but you may be sweating most of it out,” explains Dr Sohail Tanvir, Senior Registrar at Pakistan Institute of Medical Sciences. Dr Tanvir explains that the ‘eight to 10 glasses’ rule applies to people who spend most of their day indoors. For people who work outside, even 15 to 18 glasses may not be enough during hot summer days.

Kidney stones are small, hard mineral deposits that form inside your kidneys.The age bracket in which kidney stones typically occur is 18 to 30 years but they may occur outside of this bracket depending on the patient’s lifestyle and family history. Factors that commonly cause kidney stones include reduction in fluid intake, increased exercise with dehydration, medications that cause high uric acid, and a history of gout.

Diet

Patients with a history of kidney stones are advised to pass at least 2.5 litres of urine in a day. A diet low in protein and rich in oxalates (spinach, beets, potato chips, French fries, nuts and nut butters) can lead to the recurring formation of kidney stones.

Kidney stones in infants

Kidney stones may occur in infants due to Renal Tribunal Acidosis. A deficiency of inhibitors magnesium and citrate causes the process of acid absorption from the blood stream to slow down, leading to the formation of stones. If this deficiency is left untreated, it could cause kidney failure.

Types of kidney stones

Two common types of kidney stones:

Calcium Oxalates

Calcium oxalates occur when there is a high level of oxalates, found in chocolate milk, hot cocoa, tea, nuts, sesame and so on, present in the diet. The most common preventive measure is to introduce citrate into the patient’s blood stream. Citrate is the strongest inhibitors of calcium, and its supplementation will help decrease the potential to form stones in the future.

Uric Acid Stones

Uric Acid stones most commonly occur in patients with a family history of kidney stones. These stones are made of uric acid, a waste product normally passed out in the urine. They are caused by low urine output, high protein diet (especially animal protein) and inflammatory bowel disease. Uric acid stones do not show up in an ultrasound, which makes them all the more dangerous. This is why doctors need to be thorough with their testing and run an abdominal CT scan and Intravenous Pyelogram if the patient persistently complains of pain in the abdominal region.

Patients are advised to increase fluid intake, decrease protein and increase the intake of citrates in the form of citrus-rich fruits. Treatments include stone diluting tablets and surgical removal of stones.

Hurmat Majid is a subeditor at The Express Tribune. She tweets @bhandprogramme 

Published in The Express Tribune, Sunday Magazine, August 23rd, 2015.

...

 
Packaging medications together by date to be taken and time of day. PDF Print
Forbes: The idea of prepackaging pills by dosage–organizing them before they even reach the patient–isn’t new. In 2006 researchers at the Walter Reed Army Medical Center in Washington, D.C. found that by putting pills in blister packs, they upped the proportion of people who took their medicine from 61% to 97%. What is new is turning that idea into a business with the potential to rival CVS or Walgreens.

...

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 4210
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.